<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308645</url>
  </required_header>
  <id_info>
    <org_study_id>SB Injection HCC</org_study_id>
    <nct_id>NCT01308645</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)</brief_title>
  <acronym>HCC</acronym>
  <official_title>PhaseⅡ, Open Label, Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SBPharmaceutical IND, Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SBPharmaceutical IND, Co., LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of SB injection in Hepatocellular
      Carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each
      cycle). Efficacy wll be evaluated every 3 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating Tumor Response Rate</measure>
    <time_frame>4 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability scale</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine duration of response rate by measuring time to progression</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB injection</intervention_name>
    <description>Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 18 years or over

          2. Patients with Hepatocellular carcinoma progression (HCC) and primary liver cancer as a
             diagnostic imaging test (eg, X-ray, CT, scan, ultrasound) can be measured in patients
             with a lesion

          3. Directly to standard therapy (surgery, RF ablation, TACE) is not possible, patients
             with advanced liver cancer. However, the standard treatment of the subject or subjects
             entirely voluntary participation of subjects participating at the discretion of the
             doctor or researcher can be deemed included in the selected target.

          4. Life expectancy ≥ 5 months

          5. ECOG status 0, 1, 2 patients

          6. Child-Pugh classification A, B patients

          7. PLT 70,000, ANC 1,000 or more patients (OT / PT &lt;upper normal limit x 5.0, Bilirubin
             &lt;upper normal limit x 3.0)

          8. Female volunteers admitted to the study must be using a reliable means of
             contraception and must have a negative blood or urine pregnancy test at least 7 days
             ago

          9. Patients or their legal representatives who have signed the informed consent form

        Exclusion Criteria:

          1. Last 4 weeks the patients who had participated in another clinical trial

          2. Last 4 weeks the patients who received chemotherapy

          3. Associated with hepatocellular carcinoma in patients with a history of malignant tumor

          4. Hepatectomy or liver transplantation patients who received treatment.

          5. Active systemic infection requiring medical treatment

          6. Uncontrolled hypertension or diabetes mellitus.

          7. Clinically Significant cardiac disease (myocardial infarction / angina / severe
             arrhythmia / congestive heart failure)

          8. Autoimmune diseases (systemic lupus erythematosus: SLE / rheumatoid arthritis /
             myasthenia gravis) and the patients currently being treated

          9. Presence or history of malignancy other than Hepatocellular carcinoma within 5 years

         10. Patients who have history of allergy with this investigational drug.

         11. Obvious cognitive or physical impairment that would prevent participation

         12. Pregnancy, lactation period and don't using contraception earnest Patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jin woo, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Jin woo, Prof.</last_name>
    <phone>82-32-3598</phone>
    <email>jin@inha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Ji yeon, RN/BSc</last_name>
    <phone>82-32-890-1133</phone>
    <email>twindleclara@inha.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jin woo, prof.</last_name>
      <phone>28-32-890-3598</phone>
      <email>jin@inha.com</email>
    </contact>
    <contact_backup>
      <last_name>Lee Ji yeon, RN/BSc</last_name>
      <phone>82-32-890-1133</phone>
      <email>twinkleclara@inha.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Jin woo, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sbp.com</url>
    <description>Link Text : SBP</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lee Dong-heum / executive director</name_title>
    <organization>SBPharmaceutical IND, Co., LTD</organization>
  </responsible_party>
  <keyword>SBP Injection</keyword>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

